Results 171 to 180 of about 43,410 (236)

Upgrading expandable leadless pacemakers from single- to dual-chamber. [PDF]

Europace
Bongiorni MG, Doshi R, Ip JE, Exner DV, Reddy VY, Defaye P, Canby R, Shoda M, Hindricks G, Rashtian M, Neuzil P, Banker R, Delgado SM, Ganz L, Hubbard C, Bulusu A, Knops RE.   +16 more
europepmc   +1 more source

Passive transfer of human sera from chikungunya virus virus-like particle vaccine (Vimkunya) recipients fully protects non-human primates from viremia. [PDF]

NPJ Vaccines
Morello CS, Anantha R, Comer JE, Mendy J, Tindale LC, Richardson JS, Guenther B, Ho N, Cirimotich CM, Childs O'Connor C, Anderson DM, Bedell L, Warfield KL, Vang L.   +13 more
europepmc   +1 more source

Volar Locking Plate Versus External Fixation for Distal Radius Fractures: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. [PDF]

Cureus
Zahed M, Elmesalmi M, El Menawy Z, Elnaggar N, Ahmed F, Odeh M, Azaz R, Elbahnasawy SE, Elgendy HM, Hesham Gamal M.   +9 more
europepmc   +1 more source

Virus-like particles based on plant viruses and bacteriophages: emerging strategies for the delivery of nucleic acid therapeutics. [PDF]

Chem Sci
Kim D, Duoto B, Varanasi M, Goldenfeld G, Steinmetz NF.   +4 more
europepmc   +1 more source

Immunogenicity analyses and indirect ELISA application of a chimeric virus-like particle presenting a highly conserved peptide of Akabane virus Gc protein. [PDF]

Virol J
Wang J, Wei F, Yu R, Chen D, Wu S.
europepmc   +1 more source

Rapid, Scalable, and Cost-Effective Manufacturing of Uniform Non-Enveloped, Tag-Free Virus-Like Particles. [PDF]

Curr Protoc
Wang X, Gu Y, Luo H, Nowak C, Chen R, Hui Y, Liu S, Gerstweiler L.   +7 more
europepmc   +1 more source

Type I interferon signaling is required for resistance to primary influenza virus infection and vaccine-induced long-term immunity. [PDF]

J Virol
Kim K-H, Hwang HS, Pal SS, Tien Le CT, Grovenstein P, Yeasmin M, Song JM, Kwon Y-M, Wang B, Kang S-M.   +9 more
europepmc   +1 more source

Preclinical development of a cross-protective β-SARS-CoV-2 virus-like particle vaccine adjuvanted with MF59. [PDF]

NPJ Vaccines
Earnest L, Ruiz DF, Edeling MA, Montoya JC, Yap AHY, Wong CY, Holz LE, Gras S, Collett S, Cooney JP, Davidson KC, Grimley SL, Purcell DFJ, Roberts J, Mumford J, Tan CW, Wang LF, Godfrey DI, Frieman M, Hans D, Vincan E, Anderson DE, Subbarao K, Pellegrini M, Mackenzie JM, Rockman S, Heath WR, Torresi J.   +27 more
europepmc   +1 more source

Immunogenicity and efficacy of an mRNA vaccine expressing a virus-like particle spike antigen against SARS-CoV-2. [PDF]

NPJ Vaccines
Laliberte JP, Cai Y, Kenny T, Zhang Y, Ren K, Rosenthal K, Flores D, Roque R, Acton O, Peano VC, Janney N, Puri V, Siddiqui S, Pack A, Padilla G, Diallo S, Adissu H, Choudhary R, Pruitt H, Cheng YH, Thom G, Newton M, Kurokawa C, Guest J, Swanson P, Loo YM, Francica JR, Blair W, Esser M.   +28 more
europepmc   +1 more source

Marginal zone B cells mediate humoral immunity in vaccine-induced versus naturally acquired immunity against SARS-CoV-2. [PDF]

Sci Rep
Shu J, Yao J, Tan M, Sun H, Wu X, Chen F, Xuan B, Du C, Pan Y, Zhou L, Li H, Wang Y, Gan C, Tao S, Lin J, Sheng H.   +15 more
europepmc   +1 more source